Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Prostate cancer drug Eligard gets new European dosage approval
QLT USA expects the launch of Eligard 45mg six-month formulation in 23 European countries follow the implementation of this positive decision in each of the individual countries. The
QLT USA expects the launch of Eligard 45mg six-month formulation in 23 European countries follow the implementation of this positive decision in each of the individual countries. The
The NDA for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, will be reviewed as part of a two-day
The drug eliminates cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The successful completion of the clinical trial allows Kiadis Pharma
Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (DIPG) and will be used in the trial to treat recurrent diffuse intrinsic pontine glioma.
The multi-national trial will include more than 330 wet age-related macular degeneration (AMD) patients and will assess whether bevasiranib administered every eight or 12 weeks is safe and
Hereditary angieoedema (HAE) is a genetic disorder caused by a shortage of C1 inhibitor activity and results in an overreaction of the immune system. The disease is characterized
Transition and its development partner Elan have performed multiple Phase I studies evaluating the safety, tolerability and pharmacokinetic profile of ELND-005/AZD-103 in healthy volunteers. Orally administered ELND-005/AZD-103 may
Merck said that it anticipates FDA action in the second quarter of 2008. The company added that it is also moving forward as planned with filings in countries
The proof of concept clinical trial demonstrated safety and appropriate dosing of the combination regimen and showed promising clinical responses in patients under 60 years of age. Complete
The FDA stated that Fast Track designation was granted for oral azacitidine for myelodysplastic syndromes (MDS) because azacitidine, known in its injectable form as Vidaza, is approved to